A Revolutionary Approach to Cancer Treatment

Jounce Therapeutics, Inc. (NASDAQ: JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefit to patients. Jounce utilizes its Translational Science Platform to first focus on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.

Year Invested: 2013
Location: Cambridge, Mass.
Visit: www.jouncetx.com

Recent News

December 7, 2017
Jounce Therapeutics to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

November 13, 2017
Jounce Therapeutics Reports Third Quarter 2017 Financial Results

November 9, 2017
Jounce Therapeutics to Present at the Stifel 2017 Healthcare Conference

Read More News

Associated Team Members

Robert Tepper, M.D.

Cary Pfeffer, M.D.

Perry Karsen
Venture Partner

Robert Kamen, Ph.D.